Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2787+0.0017 (+0.61%)
At close: 3:58PM EDT
Advertisement
Full screen
Loading interactive chart...
  • CNW Group

    KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

    Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

  • PR Newswire

    Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

    Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.

  • GlobeNewswire

    Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

    Research to take place at Johns Hopkins, New York University and University of Alabama BirminghamDENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University (“JHU”), Ne

Advertisement
Advertisement